Literature DB >> 25755282

Vaccinia-Related Kinase 2 Controls the Stability of the Eukaryotic Chaperonin TRiC/CCT by Inhibiting the Deubiquitinating Enzyme USP25.

Sangjune Kim1, Dohyun Lee2, Juhyun Lee1, Haengjin Song2, Hyo-Jin Kim2, Kyong-Tai Kim3.   

Abstract

Molecular chaperones monitor the proper folding of misfolded proteins and function as the first line of defense against mutant protein aggregation in neurodegenerative diseases. The eukaryotic chaperonin TRiC is a potent suppressor of mutant protein aggregation and toxicity in early stages of disease progression. Elucidation of TRiC functional regulation will enable us to better understand the pathological mechanisms of neurodegeneration. We have previously shown that vaccinia-related kinase 2 (VRK2) downregulates TRiC protein levels through the ubiquitin-proteasome system by recruiting the E3 ligase COP1. However, although VRK2 activity was necessary in TRiC downregulation, the phosphorylated substrate was not determined. Here, we report that USP25 is a novel TRiC interacting protein that is also phosphorylated by VRK2. USP25 catalyzed deubiquitination of the TRiC protein and stabilized the chaperonin, thereby reducing accumulation of misfolded polyglutamine protein aggregates. Notably, USP25 deubiquitinating activity was suppressed when VRK2 phosphorylated the Thr(680), Thr(727), and Ser(745) residues. Impaired USP25 deubiquitinating activity after VRK2-mediated phosphorylation may be a critical pathway in TRiC protein destabilization.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25755282      PMCID: PMC4405641          DOI: 10.1128/MCB.01325-14

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  38 in total

1.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

Authors:  J S Steffan; A Kazantsev; O Spasic-Boskovic; M Greenwald; Y Z Zhu; H Gohler; E E Wanker; G P Bates; D E Housman; L M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.

Authors:  Anthone W Dunah; Hyunkyung Jeong; April Griffin; Yong-Man Kim; David G Standaert; Steven M Hersch; M Maral Mouradian; Anne B Young; Naoko Tanese; Dimitri Krainc
Journal:  Science       Date:  2002-05-02       Impact factor: 47.728

3.  VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancer.

Authors:  Isabel F Fernández; Sandra Blanco; José Lozano; Pedro A Lazo
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

4.  Meta-analysis and brain imaging data support the involvement of VRK2 (rs2312147) in schizophrenia susceptibility.

Authors:  Ming Li; Yi Wang; Xue-bin Zheng; Masashi Ikeda; Nakao Iwata; Xiong-jian Luo; Siow-Ann Chong; Jimmy Lee; Marcella Rietschel; Fengyu Zhang; Bertram Müller-Myhsok; Sven Cichon; Daniel R Weinberger; Manuel Mattheisen; Thomas G Schulze; Nicholas G Martin; Philip B Mitchell; Peter R Schofield; Jian-jun Liu; Bing Su
Journal:  Schizophr Res       Date:  2012-10-25       Impact factor: 4.939

Review 5.  Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders.

Authors:  Christopher A Ross
Journal:  Neuron       Date:  2002-08-29       Impact factor: 17.173

Review 6.  Glutamine repeats and neurodegeneration.

Authors:  H Y Zoghbi; H T Orr
Journal:  Annu Rev Neurosci       Date:  2000       Impact factor: 12.449

Review 7.  Cellular strategies for controlling protein aggregation.

Authors:  Jens Tyedmers; Axel Mogk; Bernd Bukau
Journal:  Nat Rev Mol Cell Biol       Date:  2010-10-14       Impact factor: 94.444

8.  Functional interaction between the ubiquitin-specific protease 25 and the SYK tyrosine kinase.

Authors:  Michael Cholay; Céline Reverdy; Richard Benarous; Frédéric Colland; Laurent Daviet
Journal:  Exp Cell Res       Date:  2009-11-10       Impact factor: 3.905

9.  Common variants at VRK2 and TCF4 conferring risk of schizophrenia.

Authors:  Stacy Steinberg; Simone de Jong; Ole A Andreassen; Thomas Werge; Anders D Børglum; Ole Mors; Preben B Mortensen; Omar Gustafsson; Javier Costas; Olli P H Pietiläinen; Ditte Demontis; Sergi Papiol; Johanna Huttenlocher; Manuel Mattheisen; René Breuer; Evangelos Vassos; Ina Giegling; Gillian Fraser; Nicholas Walker; Annamari Tuulio-Henriksson; Jaana Suvisaari; Jouko Lönnqvist; Tiina Paunio; Ingrid Agartz; Ingrid Melle; Srdjan Djurovic; Eric Strengman; Gesche Jürgens; Birte Glenthøj; Lars Terenius; David M Hougaard; Torben Ørntoft; Carsten Wiuf; Michael Didriksen; Mads V Hollegaard; Merete Nordentoft; Ruud van Winkel; Gunter Kenis; Lilia Abramova; Vasily Kaleda; Manuel Arrojo; Julio Sanjuán; Celso Arango; Swetlana Sperling; Moritz Rossner; Michele Ribolsi; Valentina Magni; Alberto Siracusano; Claus Christiansen; Lambertus A Kiemeney; Jan Veldink; Leonard van den Berg; Andres Ingason; Pierandrea Muglia; Robin Murray; Markus M Nöthen; Engilbert Sigurdsson; Hannes Petursson; Unnur Thorsteinsdottir; Augustine Kong; I Alex Rubino; Marc De Hert; János M Réthelyi; István Bitter; Erik G Jönsson; Vera Golimbet; Angel Carracedo; Hannelore Ehrenreich; Nick Craddock; Michael J Owen; Michael C O'Donovan; Mirella Ruggeri; Sarah Tosato; Leena Peltonen; Roel A Ophoff; David A Collier; David St Clair; Marcella Rietschel; Sven Cichon; Hreinn Stefansson; Dan Rujescu; Kari Stefansson
Journal:  Hum Mol Genet       Date:  2011-07-26       Impact factor: 6.150

Review 10.  PTMs in conversation: activity and function of deubiquitinating enzymes regulated via post-translational modifications.

Authors:  Benedikt M Kessler; Mariola J Edelmann
Journal:  Cell Biochem Biophys       Date:  2011-06       Impact factor: 2.194

View more
  11 in total

1.  The Vaccinia Virus (VACV) B1 and Cellular VRK2 Kinases Promote VACV Replication Factory Formation through Phosphorylation-Dependent Inhibition of VACV B12.

Authors:  Amber B Rico; Zhigang Wang; Annabel T Olson; Alexandria C Linville; Brianna L Bullard; Eric A Weaver; Clinton Jones; Matthew S Wiebe
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

Review 2.  The proteostasis network provides targets for neurodegeneration.

Authors:  Timothy Mark Newton; James Alex Duce; Elliott David Bayle
Journal:  Br J Pharmacol       Date:  2019-05-23       Impact factor: 8.739

3.  Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance.

Authors:  Sisi Chen; Yunyan Du; Bin Xu; Qing Li; Le Yang; Zi Jiang; Zhaoxia Zeng; Leifeng Chen
Journal:  Oncogene       Date:  2021-04-19       Impact factor: 9.867

4.  VRK2A is an A-type lamin-dependent nuclear envelope kinase that phosphorylates BAF.

Authors:  Danielle G May; Benjamin V Benson; Dae In Kim; Winnie G Shivega; Manaal H Ali; Randolph S Faustino; Alexandre R Campos; Kyle J Roux
Journal:  Mol Biol Cell       Date:  2017-06-21       Impact factor: 4.138

5.  A quaternary tetramer assembly inhibits the deubiquitinating activity of USP25.

Authors:  Bing Liu; Marta Sureda-Gómez; Yang Zhen; Virginia Amador; David Reverter
Journal:  Nat Commun       Date:  2018-11-26       Impact factor: 14.919

6.  Vaccinia-related kinase 2 drives pancreatic cancer progression by protecting Plk1 from Chfr-mediated degradation.

Authors:  Hengqing Zhu; Qing Li; Yulan Zhao; Hong Peng; Liangyun Guo; Jing Zhu; Zi Jiang; Zhaoxia Zeng; Bin Xu; Sisi Chen
Journal:  Oncogene       Date:  2021-06-17       Impact factor: 9.867

Review 7.  Emerging Roles of Ubiquitin-Specific Protease 25 in Diseases.

Authors:  Wenjing Zhu; Dandan Zheng; Dandan Wang; Lehe Yang; Chengguang Zhao; Xiaoying Huang
Journal:  Front Cell Dev Biol       Date:  2021-06-23

Review 8.  Post-Translational Modifications of Deubiquitinating Enzymes: Expanding the Ubiquitin Code.

Authors:  Yanfeng Wang; Feng Wang
Journal:  Front Pharmacol       Date:  2021-06-10       Impact factor: 5.810

9.  Glycogen synthase kinase 3β suppresses polyglutamine aggregation by inhibiting Vaccinia-related kinase 2 activity.

Authors:  Eunju Lee; Hye Guk Ryu; Sangjune Kim; Dohyun Lee; Young-Hun Jeong; Kyong-Tai Kim
Journal:  Sci Rep       Date:  2016-07-05       Impact factor: 4.379

Review 10.  Proteostasis and Proteotoxicity in the Network Medicine Era.

Authors:  Marta Lualdi; Tiziana Alberio; Mauro Fasano
Journal:  Int J Mol Sci       Date:  2020-09-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.